The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1245 Weight Loss articles
Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.
A new experimental medication from Karolinska Institute targets muscle metabolism rather than appetite, offering a potential alternative to Ozempic and Wegovy with fewer side effects.
Mayim Bialik, known for her roles in 'Blossom' and 'The Big Bang Theory,' recently detailed her challenging journey with GLP-1 medications, highlighting severe gastrointestinal distress and other debilitating symptoms. Her candid account serves as a crucial reminder about the potential risks and the importance of careful medical supervision when considering these powerful drugs.
New research from Stanford Medicine reveals a potential solution to the muscle loss associated with GLP-1 medications like Ozempic and Wegovy, offering hope for stronger, healthier weight loss.
The rise of GLP-1 medications is profoundly altering consumer spending habits and food preferences, forcing the grocery industry to adapt. Discover the science behind these changes and how businesses are responding.
GLP-1 medications have transformed weight management and diabetes care, but their effects extend beyond the scale. Many users report surprising changes to their libido and sexual function. This article delves into why these powerful drugs can either boost or dampen your sex drive, offering insights from leading medical experts.
The surge in popularity of GLP-1 medications like Ozempic and Wegovy has inadvertently fueled a growing 'gray market' for peptides. This unregulated trade, often facilitated by cryptocurrency, presents significant risks to consumers seeking cheaper alternatives or unapproved compounds.
A new federal agreement could lower the cost of popular weight-loss medications like Wegovy and Zepbound to $50 per month for eligible Medicare beneficiaries. Here is what you need to know about eligibility and clinical impact.
GLP-1 receptor agonists are showing promise for brain health by reducing inflammation, but experts caution that using these powerful medications solely for dementia prevention is premature, especially given mixed clinical trial results.
